EP0756491A1 - Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof - Google Patents
Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereofInfo
- Publication number
- EP0756491A1 EP0756491A1 EP94915078A EP94915078A EP0756491A1 EP 0756491 A1 EP0756491 A1 EP 0756491A1 EP 94915078 A EP94915078 A EP 94915078A EP 94915078 A EP94915078 A EP 94915078A EP 0756491 A1 EP0756491 A1 EP 0756491A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- combinations
- administered
- phosphorylated
- use according
- active ingredients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Definitions
- BNP Brain Natriuretic Peotide
- phosphorylated urodilatin phosphorylated CDD / ANP and their combinations
- the present invention relates to the use of the peptide hormones brain natriuretic peptides (BNP), phosphorylated urodilatin, phosphorylated CDD / ANP and combinations for the treatment of lung and / or bronchial diseases.
- BNP brain natriuretic peptides
- phosphorylated urodilatin phosphorylated CDD / ANP
- combinations for the treatment of lung and / or bronchial diseases.
- Obstructive respiratory diseases are characterized by a spasm of the bronchial muscles, swelling of the bronchial mucosa and increased production of bronchial secretions in various forms. They include, in particular, bronchial asthma, chronic obstructive respiratory diseases (COLD) and also cardinal asthma.
- COLD chronic obstructive respiratory diseases
- ⁇ 2 -spatomimetics e.g. fenoterol, salbutamol, terbutalen
- the ß 2 sympatomimetics reduce the tone of the smooth bronchial muscles, they also inhibit the release of mediator substances from the mast cells and increase the mucociliary clearing function.
- ⁇ 2 sympatomimetics can lead to desensitization of ⁇ 2 adrenoreceptors and thus
- bronchodilatory activity of the atrial natriuretic peptide (ANP) in asthma is known (Hulks et al., Br. Med. J. 299 (1989) -, 1081 - 1982).
- the object of the present invention was to provide a new therapeutic agent for lung and / or bronchial diseases, in particular obstructive respiratory diseases, which can be used instead of known therapeutic agents or in combination with these and known agents, such as, for. B. is superior to the atrial natriuretic peptide and urodilatin in the strength of the bronchodilatory effect.
- the object of the invention is to provide a pharmaceutical composition which contains brain natriuretic peptides (BNP), phosphorylated urodilatin, phosphorylated ANP and combinations thereof as an active ingredient and, where appropriate, conventional pharmaceutical diluents, carriers, fillers or auxiliaries for the treatment of lungs - and / - or bronchial diseases solved.
- BNP brain natriuretic peptides
- phosphorylated urodilatin phosphorylated ANP and combinations thereof as an active ingredient
- conventional pharmaceutical diluents, carriers, fillers or auxiliaries for the treatment of lungs - and / - or bronchial diseases solved.
- the pharmaceutical composition is particularly suitable for the treatment of obstructive respiratory diseases.
- composition is preferably administered parenterally, in particular intravenously (eg intravenous injections (as a bolus) or intravenous infusion) or by inhalation, the dosage preferably being from 5 ng to 1,000 ⁇ g of brain Natriuretic Peptide (BNP) per kg body weight, particularly preferably 10 ng to 100 ⁇ g Brain Natriuretic Peptide (BNP) per kg body weight.
- intravenously eg intravenous injections (as a bolus) or intravenous infusion
- BNP brain Natriuretic Peptide
- BNP Brain Natriuretic Peptide
- Intramuscular, subcutaneous, parenteral administration under protective medication is also suitable in the above doses.
- BNP brain natriuretic peptides
- phosphorylated urodilatin phosphorylated ANP
- combinations thereof in the case of bronchoconstriction caused by inhalation of acetylcholine leads to significant protection, which is improved in particular by improved forced expiration shows.
- BNP brain natriuretic peptides
- ANP atrial natriuretic peptide
- the invention is further illustrated by the following example.
- BNP Brain Natriuretic Peptide
- Brain Natriuretic Peptide achieved a pronounced bronchodilatory effect on the guinea pigs, which was clearly superior to urodilatin with the same dosage.
- the atrial natriuretic peptide showed an even less bronchodilatory effect on 18 animals than the urodilatin.
- the Brain Natriuretic Peptide was thus superior to the two peptides already described as bronchodilatory in their degree of effectiveness.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1994/001237 WO1995028952A1 (en) | 1992-12-09 | 1994-04-20 | Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof |
CA002188143A CA2188143A1 (en) | 1992-12-09 | 1994-04-20 | Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0756491A1 true EP0756491A1 (en) | 1997-02-05 |
Family
ID=4159102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94915078A Withdrawn EP0756491A1 (en) | 1994-04-20 | 1994-04-20 | Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0756491A1 (en) |
JP (1) | JPH09512024A (en) |
-
1994
- 1994-04-20 JP JP7527293A patent/JPH09512024A/en not_active Ceased
- 1994-04-20 EP EP94915078A patent/EP0756491A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9528952A1 * |
Also Published As
Publication number | Publication date |
---|---|
JPH09512024A (en) | 1997-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60100614T2 (en) | Inhalable medicinal aerosol preparation for the treatment or bowing of pain | |
EP0392300B1 (en) | Use of at least one cytokin for the manufacture of a medicament for the systemic treatment of preneoplastic lesions | |
ROBERTSON et al. | Clinical comparison of atracurium and vecuronium (Org NC 45) | |
Moss et al. | Some factors altering the severity of acute radiation pneumonitis: variation with cortisone, heparin, and antibiotics | |
DE4216133A1 (en) | Use of urodilatin in lung and bronchial diseases | |
Diefenbach et al. | Mivacurium: dose-response relationship and administration by repeated injection or infusion | |
Ramamurthy et al. | Glycopyrrolate as a substitute for atropine in neostigmine reversal of muscle relaxant drugs | |
EP1163921B1 (en) | Inhalator | |
WO1995028952A1 (en) | Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof | |
EP1978995B1 (en) | Method for the treatment and/or prophylaxis of multiple sclerosis, and use of erythropoietin for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple sclerosis | |
EP0670163A1 (en) | Use of pentoxifylline for the manufacture of a medicament for the treatment of fibrosing or granulomatosing lung diseases | |
EP0240907B1 (en) | Use of trans-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol | |
EP0756491A1 (en) | Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof | |
DE4241490A1 (en) | Brain natriuretic peptide for treating lung and bronchial diseases - more effective at bronchodilation than urodilatin used at the same doses | |
EP1429768B1 (en) | Novel medicaments for inhalation | |
EP2581082B1 (en) | Pharmaceutical composition for treating status asthmaticus | |
EP0885013B1 (en) | Use of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses for the preparation of medicaments | |
US7521438B1 (en) | Combination of loteprednol and β2-adrenoceptor agonists | |
DE60221640T2 (en) | BIMODAL DRY POWDER COMPOSITION FOR INHALATION | |
Khuenl‐Brady et al. | Interaction of ORG 9426 and some of the clinically used intravenous anaesthetic agents in the cat | |
DE69838399T2 (en) | PREPARATION FOR CONTINUOUS INTRAVENOUS ADMINISTRATION | |
DE2134899C3 (en) | Use of N-ethyl-norscopolamine methobromide | |
Jindal et al. | Relative bronchodilatory responsiveness attributable to sympathetic and parasympathetic activity in bronchial asthma | |
EP1492546B1 (en) | Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system | |
Pauwels | Inhalation device, pulmonary deposition and clinical effects of inhaled therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19961010 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE FR GB IT |
|
17Q | First examination report despatched |
Effective date: 20001108 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 38/22 A, 7A 61P 11/08 B |
|
RTI1 | Title (correction) |
Free format text: USE OF BRAIN NATRIURETIC PEPTIDES (BNP) FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF OBSTRUCTIVE PULMONARY DISORDERS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20021219 |